- Home
- CRVO vs OTLK Comparison
CRVO vs OTLK Comparison
Compare CRVO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVO | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 29.2M |
| IPO Year | 2011 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CRVO | OTLK |
|---|---|---|
| Price | $2.87 | $0.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $23.00 | $2.50 |
| AVG Volume (30 Days) | 46.7K | ★ 4.2M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $4,006,510.00 | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $0.16 |
| 52 Week High | $13.13 | $3.39 |
Technical Indicators
Market Signals| Indicator | CRVO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 23.54 | 42.53 |
| Support Level | N/A | $0.21 |
| Resistance Level | $4.27 | $0.29 |
| Average True Range (ATR) | 0.24 | 0.02 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 2.62 | 30.22 |
Price Performance
Historical ComparisonAbout CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.